Furthermore, the results presented here suggest that alarmin may be a potential therapeutic target for immunotherapy of JIA and SLE, but also suggest that HMGB1 may be a valuable laboratory biomarker. This evidence concerns the gene HMGB1 and systemic lupus erythematosus.